Growth differentiation factor 11: A new hope for the treatment of cardiovascular diseases

Cytokine Growth Factor Rev. 2023 Jun-Aug:71-72:82-93. doi: 10.1016/j.cytogfr.2023.06.007. Epub 2023 Jun 30.

Abstract

Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-β superfamily that has garnered significant attention due to its anti-cardiac aging properties. Many studies have revealed that GDF11 plays an indispensable role in the onset of cardiovascular diseases (CVDs). Consequently, it has emerged as a potential target and novel therapeutic agent for CVD treatment. However, currently, no literature reviews comprehensively summarize the research on GDF11 in the context of CVDs. Therefore, herein, we comprehensively described GDF11's structure, function, and signaling in various tissues. Furthermore, we focused on the latest findings concerning its involvement in CVD development and its potential for clinical translation as a CVD treatment. We aim to provide a theoretical basis for the prospects and future research directions of the GDF11 application regarding CVDs.

Keywords: Apoptosis; Cardiovascular diseases; GDF11; Growth differentiation factor 11; Myocardial injury.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging
  • Bone Morphogenetic Proteins / therapeutic use
  • Cardiovascular Diseases* / drug therapy
  • Growth Differentiation Factors / therapeutic use
  • Humans
  • Signal Transduction
  • Transforming Growth Factor beta

Substances

  • Growth Differentiation Factors
  • Transforming Growth Factor beta
  • GDF11 protein, human
  • Bone Morphogenetic Proteins